简讯:不可切除III期EGFR突变NSCLC放化疗后度伐利尤单抗治疗:PACIFIC研究的事后亚组分析
基于III期安慰剂对照PACIFIC研究(NCT02125461),对35例局部检测确认EGFR突变、不可切除III期NSCLC患者进行事后探索性分析,度伐利尤单抗组24例与安慰剂组11例的中位PFS分别为11.2个月与10.9个月(HR=0.91),中位OS分别为46.8个月与43.0个月(HR=1.02),置信区间宽,应谨慎解读。
要点
- EGFR突变亚组共35例(度伐利尤单抗24例,安慰剂11例),分析为事后探索性。
- 中位PFS度伐利尤单抗11.2个月 vs 安慰剂10.9个月,HR=0.91(95%CI 0.39-2.13)。
- 中位OS度伐利尤单抗46.8个月 vs 安慰剂43.0个月,HR=1.02(95%CI 0.39-2.63)。
核心结论
- 在EGFR突变肿瘤患者中,度伐利尤单抗的PFS和OS结局与安慰剂相似,置信区间宽。
- 由于患者数量少且缺乏按肿瘤生物标志物状态评估临床结局的前瞻性研究,这些数据应谨慎解读。
- 有必要进一步研究以确定不可切除III期EGFR突变NSCLC的最佳治疗。
研究设计与样本
- PACIFIC研究为III期安慰剂对照研究(NCT02125461),本文报告其EGFR突变NSCLC患者亚组的事后探索性疗效和安全性分析。
- 入组患者为不可切除III期NSCLC,接受至少2周期铂类同步放化疗后无进展,按2:1随机接受度伐利尤单抗(10 mg/kg静脉注射,每2周一次,最长1年)或安慰剂,按年龄、性别和吸烟史分层。
- 入组不限于致癌驱动基因突变状态或程序性死亡配体1表达。
- EGFR突变仅由局部检测确定。
- 主要终点为盲态独立中心审查评估的无进展生存期(PFS)和总生存期(OS),次要终点包括客观缓解率和安全性。
主要发现
- 共713例患者随机,其中35例经局部检测确认EGFR突变NSCLC(度伐利尤单抗组n=24,安慰剂组n=11)。
- 数据截止日期为2021年1月11日,亚组所有随机患者的中位随访时间为42.7个月(范围3.7-74.3个月)。
- 中位PFS为度伐利尤单抗组11.2个月(95%CI 7.3-20.7)vs 安慰剂组10.9个月(95%CI 1.9-不可评估[NE]),风险比=0.91(95%CI 0.39-2.13)。
- 中位OS为度伐利尤单抗组46.8个月(95%CI 29.9-NE)vs 安慰剂组43.0个月(95%CI 14.9-NE),风险比=1.02(95%CI 0.39-2.63)。
- 度伐利尤单抗的安全性特征与总体人群及已知特征基本一致。
局限性
- EGFR突变NSCLC亚组的统计分析为事后分析且被视为探索性。
- PFS和OS的置信区间宽。
- 患者数量少。
- 缺乏按肿瘤生物标志物状态评估临床结局的前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Consolidation durvalumab (the "PACIFIC regimen") is standard of care for patients with unresectable stage III NSCLC who have not progressed after chemoradiotherapy, on the basis of data from the phase 3 placebo-controlled PACIFIC study (NCT02125461). Nevertheless, the benefit of immunotherapy in patients with stage III EGFR-mutant (EGFRm) NSCLC is not well characterized. Here, we report a post hoc exploratory efficacy and safety analysis from a subgroup of patients with EGFRm NSCLC from the PACIFIC. METHODS: Patients with stage III unresectable NSCLC and no progression after more than or equal to two cycles of platinum-based concurrent chemoradiotherapy were randomized (2:1) to receive durvalumab (10 mg/kg intravenously every 2 weeks [wk], for up to 1 y) or placebo; stratified by age, sex, and smoking history. Enrollment was not restricted by oncogenic driver gene mutation status or programmed death-ligand 1 expression. Patients with NSCLC with an EGFR mutation, determined by local testing only, were included in this subgroup analysis. The primary end points were progression-free survival (PFS; assessed by blinded independent central review) and overall survival (OS). Secondary end points included objective response rate and safety. Statistical analyses for the subgroup of patients with EGFRm NSCLC were post hoc and considered exploratory. RESULTS: Of 713 patients randomized, 35 had locally confirmed EGFRm NSCLC (durvalumab, n = 24; placebo, n = 11). At data cutoff (January 11, 2021), median duration of follow-up for survival was 42.7 months (range: 3.7-74.3 mo) for all randomized patients in the subgroup. Median PFS was 11.2 months (95% confidence interval [CI]: 7.3-20.7) with durvalumab versus 10.9 months (95% CI: 1.9-not evaluable [NE]) with placebo; hazard ratio = 0.91 (95% CI: 0.39-2.13). Median OS was 46.8 months (95% CI: 29.9-NE) with durvalumab versus 43.0 months (95% CI: 14.9-NE) with placebo; hazard ratio = 1.02 (95% CI: 0.39-2.63). The safety profile of durvalumab was generally consistent with the overall population and known profile for durvalumab. CONCLUSIONS: PFS and OS outcomes with durvalumab were similar to placebo for patients with EGFRm tumors, with wide CIs. These data should be interpreted with caution owing to small patient numbers and lack of a prospective study that evaluates clinical outcomes by tumor biomarker status. Further research to determine the optimal treatment for unresectable stage III EGFRm NSCLC is warranted.
引用
- Naidoo J, Antonia S, Wu YL, et al. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. J Thorac Oncol. 2023. PMID: 36841540. doi:10.1016/j.jtho.2023.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。